Sign in

Christoffer Merrild

@c-merrild.bsky.social
5 followers 12 following 5 posts

PhD-fellow at Christoffer Clemmensen's laboratory, Novo Nordisk Foundation Center for Basic Metabolic Research. Basic researcher, founder & ecosystem builder

PostsRepliesMedia
Christoffer Merrild @c-merrild.bsky.social · 16/09/2026
It's out now in Nature Metabolism 💉 Most obesity meds hit 1-2 hormone receptors (GLP-1R ± GIPR), and they're quite effective, but doses a being pushed to achieve greater weight loss = more side effects. We combined retatrutide (GLP-1R/GIPR/GCGR) with cagrilintide (AMLNR/CALCR) in obese rats.
nature.com
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats - Nature Metabolism
Combination therapy with retatrutide and cagrilintide lowers body weight and improves markers of metabolic health in obese, male rats more efficiently than equimolar monotherapies and matched-dose com...
252
Christoffer Merrild @c-merrild.bsky.social · 07/04/2026
In our new paper in the special issue at @jphysiol.bsky.social, we show that FGF21-glucagon signalling drives sex-specific effects on weight loss and glucose tolerance in obese mice, and uncover an unexpected FGF21-deficiency-driven susceptibility to obesity in females.
131